Cargando…

Ecteinascidin-743: Evidence of Activity in Advanced, Pretreated Soft Tissue and Bone Sarcoma Patients

Purpose. To evaluate the activity and safety of ecteinascidin (ET-743) in pretreated patients with advanced or metastatic soft tissue and bone sarcoma. Patients or subjects. Eighty-nine patients received ET-743 as a 24-hour continuous infusion at a dose of 900–1500 μg/m(2) every 3 weeks. Results. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Huygh, G., Clement, Paul M. J., Dumez, H., Schöffski, P., Wildiers, H., Selleslach, J., Jimeno, J. M., Wever, I. De, Sciot, R., Duck, L., Van Oosterom, A. T.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1820623/
https://www.ncbi.nlm.nih.gov/pubmed/17496996
http://dx.doi.org/10.1155/SRCM/2006/56282
_version_ 1782132643208364032
author Huygh, G.
Clement, Paul M. J.
Dumez, H.
Schöffski, P.
Wildiers, H.
Selleslach, J.
Jimeno, J. M.
Wever, I. De
Sciot, R.
Duck, L.
Van Oosterom, A. T.
author_facet Huygh, G.
Clement, Paul M. J.
Dumez, H.
Schöffski, P.
Wildiers, H.
Selleslach, J.
Jimeno, J. M.
Wever, I. De
Sciot, R.
Duck, L.
Van Oosterom, A. T.
author_sort Huygh, G.
collection PubMed
description Purpose. To evaluate the activity and safety of ecteinascidin (ET-743) in pretreated patients with advanced or metastatic soft tissue and bone sarcoma. Patients or subjects. Eighty-nine patients received ET-743 as a 24-hour continuous infusion at a dose of 900–1500 μg/m(2) every 3 weeks. Results. We observed one complete remission, 5 partial remissions, one minimal response, and 16 patients with a disease stabilization of 6 months or more. The objective response rate was 6.7% and the clinical benefit rate at 3 and 6 months was 37.7% and 23.4%, respectively. Responses were noted in patients with lipo-, leiomyo-, osteo-, and myogenic sarcoma, with a median duration of 9.85 months. Toxicity mainly involved an asymptomatic elevation of transaminases and neutropenia. Estimated 1- and 2-year survival rates were 39.4% and 15.8%. Median overall survival was 8.25 months. Discussion. This retrospective analysis confirms that ET-743 induces objective responses and progression arrest in a clinically relevant proportion of patients.
format Text
id pubmed-1820623
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-18206232007-03-26 Ecteinascidin-743: Evidence of Activity in Advanced, Pretreated Soft Tissue and Bone Sarcoma Patients Huygh, G. Clement, Paul M. J. Dumez, H. Schöffski, P. Wildiers, H. Selleslach, J. Jimeno, J. M. Wever, I. De Sciot, R. Duck, L. Van Oosterom, A. T. Sarcoma Clinical Study Purpose. To evaluate the activity and safety of ecteinascidin (ET-743) in pretreated patients with advanced or metastatic soft tissue and bone sarcoma. Patients or subjects. Eighty-nine patients received ET-743 as a 24-hour continuous infusion at a dose of 900–1500 μg/m(2) every 3 weeks. Results. We observed one complete remission, 5 partial remissions, one minimal response, and 16 patients with a disease stabilization of 6 months or more. The objective response rate was 6.7% and the clinical benefit rate at 3 and 6 months was 37.7% and 23.4%, respectively. Responses were noted in patients with lipo-, leiomyo-, osteo-, and myogenic sarcoma, with a median duration of 9.85 months. Toxicity mainly involved an asymptomatic elevation of transaminases and neutropenia. Estimated 1- and 2-year survival rates were 39.4% and 15.8%. Median overall survival was 8.25 months. Discussion. This retrospective analysis confirms that ET-743 induces objective responses and progression arrest in a clinically relevant proportion of patients. Hindawi Publishing Corporation 2006 2006-12-31 /pmc/articles/PMC1820623/ /pubmed/17496996 http://dx.doi.org/10.1155/SRCM/2006/56282 Text en Copyright © 2006 G. Huygh et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Huygh, G.
Clement, Paul M. J.
Dumez, H.
Schöffski, P.
Wildiers, H.
Selleslach, J.
Jimeno, J. M.
Wever, I. De
Sciot, R.
Duck, L.
Van Oosterom, A. T.
Ecteinascidin-743: Evidence of Activity in Advanced, Pretreated Soft Tissue and Bone Sarcoma Patients
title Ecteinascidin-743: Evidence of Activity in Advanced, Pretreated Soft Tissue and Bone Sarcoma Patients
title_full Ecteinascidin-743: Evidence of Activity in Advanced, Pretreated Soft Tissue and Bone Sarcoma Patients
title_fullStr Ecteinascidin-743: Evidence of Activity in Advanced, Pretreated Soft Tissue and Bone Sarcoma Patients
title_full_unstemmed Ecteinascidin-743: Evidence of Activity in Advanced, Pretreated Soft Tissue and Bone Sarcoma Patients
title_short Ecteinascidin-743: Evidence of Activity in Advanced, Pretreated Soft Tissue and Bone Sarcoma Patients
title_sort ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1820623/
https://www.ncbi.nlm.nih.gov/pubmed/17496996
http://dx.doi.org/10.1155/SRCM/2006/56282
work_keys_str_mv AT huyghg ecteinascidin743evidenceofactivityinadvancedpretreatedsofttissueandbonesarcomapatients
AT clementpaulmj ecteinascidin743evidenceofactivityinadvancedpretreatedsofttissueandbonesarcomapatients
AT dumezh ecteinascidin743evidenceofactivityinadvancedpretreatedsofttissueandbonesarcomapatients
AT schoffskip ecteinascidin743evidenceofactivityinadvancedpretreatedsofttissueandbonesarcomapatients
AT wildiersh ecteinascidin743evidenceofactivityinadvancedpretreatedsofttissueandbonesarcomapatients
AT selleslachj ecteinascidin743evidenceofactivityinadvancedpretreatedsofttissueandbonesarcomapatients
AT jimenojm ecteinascidin743evidenceofactivityinadvancedpretreatedsofttissueandbonesarcomapatients
AT weveride ecteinascidin743evidenceofactivityinadvancedpretreatedsofttissueandbonesarcomapatients
AT sciotr ecteinascidin743evidenceofactivityinadvancedpretreatedsofttissueandbonesarcomapatients
AT duckl ecteinascidin743evidenceofactivityinadvancedpretreatedsofttissueandbonesarcomapatients
AT vanoosteromat ecteinascidin743evidenceofactivityinadvancedpretreatedsofttissueandbonesarcomapatients